LabGenius Therapeutics https://validator.w3.org/feed/docs/rss2.html AACR Annual Meeting Press release | LabGenius Therapeutics Announces Poster Presentation at the AACR Annual Meeting 2026 Article | Smart Antibodies Will Transform Our Fight Against Solid Tumours News Pipeline Publication | Engineering multispecific antibodies with complete killing selectivity through closed-loop integration of machine learning and high-throughput experimentation Item #1 Hitesh Sanganee William Strohl LabGenius Article | Designed by AI: the future of antibody drugs Michael Dustin Vivek Subbiah Bio-Europe Spring NextGen Biomed Article | The autonomous lab Interview | Leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimisation Robert Lutz Hendrik-Tobias Arkenau Gino Van Heeke Blueprint Series | This AI is Creating Cancer-Killing Molecules Publication | 3in1: an ultra-fast phage display biopanning method overcoming the biopanning bias and yielding more diverse binders Press release | LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025 Angus Sinclair Technology Contact Us Careers Press release | LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes Press release | LabGenius Therapeutics Appoints Dr. Angus Sinclair as Chief Scientific Officer Terms of Use Christian Uhrich Oliver Sims Edwin Moses Interview | Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation James Field Sasha Vidiborskiy Podcast | ‘Show me the molecule’ – On synthetic biology and cutting through AI hype Press release | LabGenius Therapeutics Appoints Three Experts to its Team of Scientific Advisors Edward de Moraville James Field Winston Haynes Dan Foxler Press release | LabGenius Appoints Dr. Hannah Seitz as Chief Business Officer Press release | LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark Press release | LabGenius’ Research Collaboration with Sanofi Yields Positive Results Catherine Howsham Lucy Shaw Mohammad Akhlaq Hannah Seitz Michael Mullin